ABSTRACT
BACKGROUND: The platinum-based combined chemotherapy is effective for advanced non-small cell lung cancer (NSCLC). This study is to observe the clinical effect and toxicity of combination of gemcitabine with cisplatin for advanced NSCLC. METHODS: All of 32 patients were pathologically confirmed as stage III or IV NSCLC who lost chance to receive operation. Gemcitabine was given on days 1, 8, 15 at a dose of 1000mg/m² and cisplatin on days 1-5 at a dose of 20mg. The chemotherapy was repeated every 28 days up to 3-4 cycles. RESULTS: There was no patient who got complete response, and the overall response rate was 34.4% (11/32). The median survival duration was 329 days and the 1-year survival rate was 32.7%. The main toxicities were myelosuppression, nausea and vomiting, however, there was no severe grade IV damage or obvious liver and kidney damage. No one was delayed for chemotherapy due to adverse effect. CONCLUSIONS: The combination of gemcitabine and cisplatin is effective and well tolerated in the treatment of advanced NSCLC.
ABSTRACT
A simple, rapid, sensitive column-switching HPLC method is described for the analysis of the 10-hydroxycamptothecin (HCPT) in human serum. A pre-column containing restricted access media (RAM) is used for the sample clean-up and trace enrichment and is combined with a C18 column for the final separation. The analytical time is 8 min. The HCPT is monitored with fluorescence detector, excitation and emission wavelengths being 385 and 539 nm, respectively. There is a linear response range of 1-1000 ng/ml with correlation coefficient of 0.998 while the limit of quantification is 0.1 ng/ml. The intra-day and inter-day variations are less than 5%. This analytic procedure has been applied to a pharmacokinetic study of HCPT in clinical patients and the pharmacokinetic parameters of one-compartment model are calculated.
Subject(s)
Antineoplastic Agents, Phytogenic/blood , Camptothecin/analogs & derivatives , Camptothecin/blood , Chromatography, High Pressure Liquid/methods , Antineoplastic Agents, Phytogenic/pharmacokinetics , Calibration , Camptothecin/pharmacokinetics , Chromatography, High Pressure Liquid/instrumentation , Humans , Reference Standards , Reference Values , Sensitivity and Specificity , Spectrometry, FluorescenceABSTRACT
The efficacy and safety of Lishengsu (a rhG-CSF preparation) were evaluated for treatment of chemotherapy-induced leukopenia. 327 cases of leukopenia with grade I-IV induced by chemotherapy were subcutaneously administered at 2.5 - 5.0 micro g/(kg x d) of Lishengsu, and hemogram and the side effects were observed. The results showed that Lishengsu had satisfactory effect to cure leukopenia after chemtherapy, with an effective rate of 99.4% (325/327), the side effects were quite slight. It is concluded that Lishengsu is efficient and safe for patients with leukopenia, and can be used as an adjuvant drug for treatment of leukopenia after chemotherapy.